BRIEF—MedPharm gets equity investment from Ampersand Capital Partners

MedPharm, a UK-based provider of contract topical and transdermal product design and formulation development services, says it has received a multi-million dollar investment by Ampersand Capital Partners.The actual sum of the investment was not disclosed

Since its founding almost 20 years ago, MedPharm has established itself as a trusted developer of topical and transdermal products for the pharmaceutical drug development communities worldwide. The company’s services currently encompass formulation development, performance testing and clinical trials manufacturing at its facilities in Guildford, UK and Durham, North Carolina, USA.

MedPharm’s founders, Dr Andrew Muddle and Prof Marc Brown, will remain with the company to work with its growing executive team to expand MedPharm’s service offering in topical and transdermal pharmaceutical development and manufacturing, as well as increase international CDMO market coverage.

Ampersand general partner David Parker commented: “MedPharm is an excellent fit with Ampersand’s strategy of investing in growth-oriented businesses that have established leadership positions in specialty segments of the CDMO market.”